We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
Looking for a particular Menlo Therapeutics Inc. employee's phone or email?
The Menlo Therapeutics Inc. annual revenue was $10 million in 2026.
Mutya Harsch is the Chief Legal Officer, General Counsel and Secretary of Menlo Therapeutics Inc..
1 people are employed at Menlo Therapeutics Inc..
Menlo Therapeutics Inc. is based in Redwood City, California.
The NAICS codes for Menlo Therapeutics Inc. are [32541, 5417, 541, 32, 3254, 325, 54].
The SIC codes for Menlo Therapeutics Inc. are [873, 87].